Furthermore, existing evidence suggests that patients with DLBCL having TP53 mutations receiving rituximab plus CHOP (R–CHOP) exhibit worse OS and PFS compared to those without mutations (13, 25). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.